Curetis, Heraeus Medical Partner to Develop MDx Test for Implant, Tissue Infections | GenomeWeb

German molecular diagnostics firm Curetis and technology group Heraeus Medical said today that they have signed an agreement to jointly develop a cartridge for use on Curetis' Unyvero system to detect pathogens and antibiotic resistance in implant and tissue infections.

Terms of the agreement call for Heraeus and Curetis to co-fund product development. Heraeus' customers will be given access to the Curetis Unyvero nucleic acid testing platform, and Curetis will pay a sales commission for any customers that Heraeus refers to Curetis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.